Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

LEUKOCARE Licenses Biomarker Cell-Free DNA to Trillium Diagnostics

Published: Wednesday, October 10, 2012
Last Updated: Wednesday, October 10, 2012
Bookmark and Share
Trillium to develop a commercial IVD assay kit for early diagnosis of infection/sepsis.

LEUKOCARE AG and Trillium Diagnostics, LLC have announced that both partners have formed a strategic alliance regarding the development and marketing of LEUKOCARE’s patented method for the detection of inflammatory activity using the novel biomarker circulating cell-free DNA (cf-DNA).

Trillium will use the technology to develop a commercial assay for the diagnosis of sepsis.

Neutrophil-derived DNA is the major component of cf-DNA, which has recently been recognized as an important predictive biomarker in severely ill patients with acute or chronic inflammatory disorders.

LEUKOCARE has granted to Trillium an exclusive, royalty-bearing license of its patent and know-how for the method of measuring the quantity of cf-DNA to develop a commercial IVD assay kit for the worldwide market.

Trillium intends to establish a cf-DNA test as a simple and cost effective tool for healthcare professionals to obtain clinically informative data on patients with suspected infection/sepsis.

The development process is expected to return an approved and marketable assay in about 2 years’ time.

"A prognostic assay for sepsis will represent a tremendous improvement in intensive care medicine," said Bruce Davis, M.D., CEO and President of Trillium Diagnostics.

Davis continued, "It clearly would fulfil an unmet medical need to help identify sepsis patients at early stage and to initiate rapid treatment actions."

Dr Davis added, “cf-DNA is an important addition to our patented infection/sepsis diagnostic assays of neutrophil CD64 expression (Leuko64 assay) and soluble CD163 (Macro163 assay). We hope these three assays used in parallel will provide unparalleled sensitivity and specificity in diagnosis.”

Michael Scholl, CEO of LEUKOCARE, said: “We have found a strong and competent partner in Trillium. Its pertinent expertise in developing and marketing diagnostic assays will make the best use of the potential of the cf-DNA biomarker. LEUKOCARE will participate in the future success of the product by significant royalties.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Thousands of Protein Interactions Identified
Thanks to the work by Utrecht University researcher Fan Liu and her colleagues, it is now possible to map the interactions between proteins in human cells.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Cell-Cell Repulsion Mystery Solved
University of Basel findings could be important for cancer research.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos